RARITAN, New Jersey, Sept. 9 -- Johnson and Johnson Innovative Medicine issued the following news release on Sept. 8, 2026:

* * *

Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026

First presentation of pivotal Phase 3 CAPLYTA(R) data in adults with bipolar mania underscores the asset's potential across mood disorders

New SPRAVATO(R) analyses and schizophrenia . . .

Click here for more information about our products